Skip to content

Opinion

Rx should close ranks behind Walgreens

Much has been written about Walgreens’ struggle to flourish in the aftermath of the drug chain’s decision to discontinue its relationship with Express Scripts, one of America’s most important pharmacy benefit managers.

Outlook for biopharmaceutical sector is bright

patent cliffs, stagnant pipelines, the end of the blockbuster era, etc. In reality, the prospects of the biopharmaceutical sector — for patients in search of new medicines, for policy makers seeking value in the health care system and for

Bloom’s arrival a catalyst for Family Dollar

If initial indications offer any guarantee of an eventual outcome, Mike Bloom’s arrival as president and chief operating officer at Family Dollar Stores promises to benefit the dollar retailer in ways almost too numerous to detail.

Rx has means to counter budget cutters

Retail pharmacy operators continue to find themselves on the firing line as government officials work to rein in health care spending and address worrisome long-term budget deficits. Medicaid, the federal/state program that provides health care for the indigent, is a case in point.

Walgreens makes more stunning changes

Change never comes easily, especially for a company blessed with success. Why change, the thinking goes, when what we’re doing apparently works so well? That’s been Walgreens’ dilemma. Very few retailers, and no drug chains, have enjoyed the success Walgreens has found over the past 30 years.

Healthier Rite Aid is boost for industry

It’s time for people in the chain drug industry to take another look at Rite Aid, whose long, painful turnaround has started to gain traction in recent months. For more than a decade the company has been widely viewed as something of an invalid, a status that resulted from self-inflicted wounds.

There is simply no one to replace DeMino

The people who founded, built and served the chain drug industry in this country during its halcyon days are rapidly disappearing from the scene. During the summer death claimed Charlie Bowlus, the founder and driving force behind ECRM.

High Court should weigh in on health care reform

Whatever one thinks of the health care reform legislation, whose most far-reaching provisions are due to take effect in 2014, it should be welcome news that the Obama administration has asked the Supreme Court to consider the ongoing legal challenges to the law.

Cosby will bring change to CVS/pharmacy

or even distant — memory has a mass retailer tapped an outsider to head up its executive ranks. Yet that’s what is about to happen, on October 1, when Mark Cosby officially becomes president of the CVS/pharmacy unit of CVS Caremark. It is a daunting assignment. Depending on how one calculates

Giancamilli helps move community Rx ahead

When Andy Giancamilli steps down as chief executive officer of Katz Group Canada at the beginning of February, his move to an advisory role at the company will mark the end of a career in community pharmacy that exemplifies what the profession means for the people who practice it and the patients it